New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

The role that artificial intelligence (AI) and other technology can play in care delivery is growing, said Coral Omene, MD, ...

Epcoritamab demonstrated a median CR of 36 months and a median progression-free survival of 37 months in LBCL patients.

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).

Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia ...

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary ...

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by ...

For children with severe Crohn disease, upadacitinib offers an effective induction therapy, but its benefits must be ...

Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further ...

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition ...

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving ...